Caprock Group’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.45M | Sell |
26,084
-127
| -0.5% | -$6.88K | 0.04% | 443 |
|
|
2025
Q4 | $1.3M | Buy |
26,211
+3,746
| +17% | +$175K | 0.03% | 533 |
|
|
2025
Q3 | $901K | Buy |
+22,465
| New | +$878K | 0.02% | 603 |
|
|
2025
Q1 | $772K | Sell |
19,752
-190
| -1% | -$6.96K | 0.02% | 553 |
|
|
2024
Q4 | $684K | Buy |
19,942
+1,424
| +8% | +$51.3K | 0.02% | 521 |
|
|
2024
Q3 | $764K | Sell |
18,518
-7,482
| -29% | -$306K | 0.03% | 461 |
|
|
2024
Q2 | $1.01M | Buy |
26,000
+13,943
| +116% | +$587K | 0.04% | 366 |
|
|
2024
Q1 | $522K | Buy |
12,057
+544
| +5% | +$22.4K | 0.03% | 398 |
|
|
2023
Q4 | $430K | Buy |
11,513
+317
| +3% | +$11.4K | 0.03% | 430 |
|
|
2023
Q3 | $409K | Sell |
11,196
-4,183
| -27% | -$148K | 0.03% | 411 |
|
|
2023
Q2 | $553K | Buy |
15,379
+1,259
| +9% | +$45.2K | 0.04% | 355 |
|
|
2023
Q1 | $507K | Buy |
14,120
+2,338
| +20% | +$81.8K | 0.04% | 358 |
|
|
2022
Q4 | $419K | Sell |
11,782
-2,013
| -15% | -$67.1K | 0.04% | 328 |
|
|
2022
Q3 | $410K | Buy |
13,795
+965
| +8% | +$36.6K | 0.04% | 324 |
|
|
2022
Q2 | $703K | Buy |
12,830
+840
| +7% | +$46.4K | 0.07% | 212 |
|
|
2022
Q1 | $662K | Buy |
11,990
+5,293
| +79% | +$287K | 0.06% | 235 |
|
|
2021
Q4 | $374K | Buy |
+6,697
| New | +$348K | 0.03% | 355 |
|
|
2021
Q3 | – | Sell |
-4,549
| Closed | -$229K | – | 559 |
|
|
2021
Q2 | $229K | Buy |
+4,549
| New | +$219K | 0.02% | 459 |
|
|
2020
Q4 | – | Sell |
-6,933
| Closed | -$339K | – | 487 |
|
|
2020
Q3 | $339K | Sell |
6,933
-14,632
| -68% | -$733K | 0.05% | 268 |
|
|
2020
Q2 | $1.11M | Buy |
21,565
+6,139
| +40% | +$315K | 0.17% | 108 |
|
|
2020
Q1 | $735K | Buy |
15,426
+9,642
| +167% | +$514K | 0.14% | 116 |
|
|
2019
Q4 | $343K | Buy |
5,784
+1,100
| +23% | +$61.2K | 0.06% | 223 |
|
|
2019
Q3 | $253K | Buy |
4,684
+173
| +4% | +$8.9K | 0.05% | 269 |
|
|
2019
Q2 | $229K | Sell |
4,511
-699
| -13% | -$35.1K | 0.04% | 279 |
|
|
2019
Q1 | $280K | Sell |
5,210
-1,014
| -16% | -$50.7K | 0.05% | 276 |
|
|
2018
Q4 | $301K | Buy |
6,224
+786
| +14% | +$38.7K | 0.07% | 239 |
|
|
2018
Q3 | $276K | Buy |
5,438
+427
| +9% | +$21.7K | 0.06% | 290 |
|
|
2018
Q2 | $256K | Buy |
5,011
+670
| +15% | +$33.7K | 0.05% | 334 |
|
|
2018
Q1 | $216K | Buy |
+4,341
| New | +$202K | 0.05% | 374 |
|
|
2017
Q4 | – | Sell |
-16,953
| Closed | -$871K | – | 479 |
|
|
2017
Q3 | $871K | Sell |
16,953
-70
| -0.4% | -$3.55K | 0.18% | 116 |
|
|
2017
Q2 | $929K | Sell |
17,023
-1,009
| -6% | -$53.8K | 0.21% | 103 |
|
|
2017
Q1 | $950K | Buy |
18,032
+953
| +6% | +$48.3K | 0.22% | 84 |
|
|
2016
Q4 | $822K | Sell |
17,079
-18,305
| -52% | -$904K | 0.21% | 103 |
|
|
2016
Q3 | $1.91M | Sell |
35,384
-128
| -0.4% | -$7.02K | 0.43% | 50 |
|
|
2016
Q2 | $1.92M | Sell |
35,512
-514
| -1% | -$27.1K | 0.47% | 51 |
|
|
2016
Q1 | $1.83M | Buy |
+36,026
| New | +$1.79M | 0.43% | 45 |
|
Other funds holding GSK
JEST
Caprock Group's GSK Position: Q1 2026 in Review
Caprock Group reduced its GSK (GSK) stake by 0.48% in Q1 2026, selling an estimated $6.88K and leaving 26,084 shares worth $1.45M. The position accounts for 0.04% of the portfolio, ranked #443.
Caprock Group first reported a position in GSK in Q1 2016 and has held it in 36 quarters since. The position peaked at $1.92M in Q2 2016. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.
- Caprock Group held 26,084 shares of GSK worth $1.45M as of Q1 2026.
- Caprock Group sold 127 GSK shares in Q1 2026, an estimated $6.88K.
- GSK made up 0.04% of Caprock Group's portfolio in Q1 2026, its #443 holding.
- Caprock Group first reported a position in GSK in Q1 2016 and has held it in 36 quarters since.
- Caprock Group's GSK position peaked at $1.92M in Q2 2016.
- 1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.
Based on Caprock Group's 13F filing for Q1 2026, filed 11 May 2026.